Valuation: Altimmune, Inc.

Market Cap 434M 387M 358M 326M 611M 41.13B 621M 4.3B 1.69B 21.49B 1.63B 1.59B 68.71B P/E 2026 *
-3.83x
P/E 2027 * -3.51x
Enterprise Value -6.73M -6M -5.55M -5.05M -9.48M -638M -9.63M -66.61M -26.19M -333M -25.23M -24.71M -1.07B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.57%
Yield 2026 *
-
Yield 2027 * -
1 day+1.36%
1 week-12.89%
Current month-22.03%
1 month-31.38%
3 months-22.30%
6 months-36.29%
Current year-38.23%
1 week 2.17
Extreme 2.17
2.41
1 month 2.17
Extreme 2.17
3.42
Current year 2.17
Extreme 2.17
6.44
1 year 2.17
Extreme 2.17
6.44
3 years 2.09
Extreme 2.09
14.84
5 years 2.09
Extreme 2.09
23.49
10 years 1.51
Extreme 1.51
237.3
Manager TitleAgeSince
Chief Executive Officer 58 01/01/2026
Director of Finance/CFO 70 11/11/2024
Chief Tech/Sci/R&D Officer - 01/05/2025
Director TitleAgeSince
Director/Board Member 58 01/09/2003
Chairman 78 01/01/2018
Director/Board Member 76 01/07/2012
Date Insider Type Main position Quantity % Market Cap. Importance
01/10/26 Exercice

Chief Financial Officer

33,329 0.0171%
01/10/26 Exercice

Chief Technology Officer

87,679 0.0451%
16/09/26 Exercice

Executive/Senior Manager

54,826 0.0282%
Change 5-day change 1-year change 3-year change Capi.($)
+1.36%-12.89%-41.78%-4.29% 434M
+1.52%-7.19%+51.66%+69.99% 65.83B
+1.52%+6.83%+10.77%+79.30% 51.87B
+0.30%-0.46%+2.53%+61.89% 51.2B
-0.38%+1.40%+29.98%+42.37% 43.76B
+0.30%+5.64%+16.99%+133.30% 42.09B
+2.35%-6.08%+236.69%+528.10% 39.04B
+2.16%+9.87%+18.92%+59.70% 34B
+5.50%-0.78%+41.41%+10.30% 25.2B
+1.60%+2.21%+21.34%+28.00% 22.8B
Average +1.62%-1.61%+38.85%+100.87% 37.62B
Weighted average by Cap. +1.41%-0.17%+46.54%+114.02%

Financials

2026 *2027 *
Net sales - -
Net income -99.55M -88.74M -82.2M -74.74M -140M -9.44B -143M -986M -388M -4.93B -373M -366M -15.77B -117M -104M -96.43M -87.67M -165M -11.07B -167M -1.16B -455M -5.79B -438M -429M -18.5B
Net Debt -440M -393M -364M -331M -621M -41.76B -631M -4.36B -1.72B -21.83B -1.65B -1.62B -69.78B -332M -296M -274M -249M -467M -31.45B -475M -3.29B -1.29B -16.44B -1.24B -1.22B -52.54B
Projected Income Statement - Annual - Altimmune, Inc.
Logo Altimmune, Inc.
Altimmune, Inc. is a late clinical-stage biopharmaceutical company. The Company is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, whereas the activation of GLP-1 receptors mediates suppression of appetite and reduction of cravings as well as metabolic effects such as weight loss. It has completed phase II development of pemvidutide. It also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
Employees
57
Date Price Change Volume
19/10/26 $2.230 +1.36% 2,611,296
16/10/26 $2.200 -6.78% 4,243,455
15/10/26 $2.360 +2.16% 3,353,751
14/10/26 $2.310 -4.94% 5,626,994
13/10/26 $2.430 -5.08% 3,717,587
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Altimmune, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
2.230USD
Average target price
17.11USD
Spread / Average Target
+667.31%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Altimmune, Inc.